wave

QUADRA FAQs

Why should I participate in the QUADRA clinical research trial?

By participating in QUADRA, you are helping to advance our knowledge of cancer and improve care for people who are affected by ovarian cancer.

What is the purpose of the QUADRA clinical trial?

The QUADRA clinical trial is being done to find out if niraparib, an investigational drug called a PARP inhibitor, can help delay the worsening of ovarian, peritoneal, or fallopian tube cancer among patients who have had 3 or 4 previous chemotherapy regimens.

What is niraparib?

Niraparib is a PARP inhibitor. PARP inhibitors are a class of medications that were found in earlier studies to be effective against recurrent ovarian cancer. PARP inhibitors block an enzyme used by cancer cells to repair breaks in their DNA. When they can’t mend their DNA, the cancer cells die. Theoretically, these drugs should spare healthy (non-cancerous) cells. Because niraparib is not yet approved by any regulatory body, it is not available outside clinical trials.

To learn more about PARP inhibitors, click here.

What happens during the trial?

About 400 people will participate in the clinical research trial. All participants will receive the study medication (niraparib). Participants will take up to three pills once a day. Treatment will continue until the disease progresses or the participant chooses to discontinue.

What are the benefits of being in the trial?

When you participate in a clinical research trial, you are playing an important role in advancing science that can result in more effective treatments for individuals like you who are affected by ovarian cancer.

For more information on the QUADRA clinical research trial, please contact a research site near you.